Research Analysts’ Weekly Ratings Changes for Quince Therapeutics (QNCX)

Several brokerages have updated their recommendations and price targets on shares of Quince Therapeutics (NASDAQ: QNCX) in the last few weeks:

• 9/24/2026 – Quince Therapeutics is now covered by Rodman & Renshaw. They set a “buy” rating and a $70.00 price target on the stock.
• 9/24/2026 – Quince Therapeutics was upgraded by Rodman & Renshaw to “strong-buy”.
• 9/22/2026 – Quince Therapeutics was upgraded by Citigroup Inc. from “market perform” to “outperform”.
• 9/22/2026 – Quince Therapeutics was upgraded by Citizens Jmp from “market perform” to “outperform”. They now have a $77.00 price target on the stock.
• 8/27/2026 – Quince Therapeutics was upgraded by Craig Hallum to “strong-buy”.
• 8/26/2026 – Quince Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/22/2026 – Quince Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/20/2026 – Quince Therapeutics is now covered by Craig Hallum. They set a “buy” rating and a $68.00 price target on the stock.
• 8/18/2026 – Quince Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $70.00 price target on the stock.
• 8/12/2026 – Quince Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/29/2026 – Quince Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/29/2026 – Quince Therapeutics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $82.00 price target on the stock.

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company’s research centers on its erythrocyte-derived extracellular vesicle (EEV) platform, which uses patients’ red blood cells to encapsulate and deliver therapeutic compounds.

Quince’s lead investigational product is eDSP, formerly known as EryDex, an autologous red-blood-cell-based formulation of dexamethasone sodium phosphate being developed for ataxia-telangiectasia (A-T).